Project Number 5U01AG010483-19 Agency/Funding Organization NIA Funding Year 2009 View Full Project Details for A TRIAL OF TTP488 TO SLOW THE RATE OF CLINICAL PROGRESSION OF PATIENTS WITH AD Research Categorization Primary Disease / Condition Alzheimer's Disease CADRO Category C. Translational Research and Clinical Interventions 7. Early-stage Clinical Drug Development (Phase I and II Clinical Trials) r. Multi-target Category G. Consortia and Public Private Partnerships 1. Consortia Researcher and Organization Principal Investigator GALASKO, DOUGLAS R Principal Investigator First Name DOUGLAS Principal Investigator Last Name GALASKO Awardee Organization UNIVERSITY OF CALIFORNIA SAN DIEGO Awardee State California Contact PI Country United States Project Detail FY Overall Cost $1,362,818 Funding Organization Agency/Funding Organization NIA Funding Organization Country United States Program Official RYAN, LAURIE M Special Initiative Alzheimer's Disease Cooperative Study (ADCS) Related Resources Repository [NIAGADS] Transethnic GWAS Summary Statistics - Jun et al. (2017) [NIAGADS] ADGC African American Summary Statistics- Reitz et al. (2013) [NIAGADS] ADGC Neuropath Summary Stats and Phenotypes- Beecham et al. (2014) [NIAGADS] ADGC Summary Statistics- Naj et al. (2011) [AlzPED] CRF receptor-1 antagonism mitigates Aβ pathology and cognitive and synaptic deficits in a mouse model of Alzheimer's disease [AlzPED] Corticotropin-Releasing Factor Receptor-1 Antagonism Reduces Oxidative Damage in an Alzheimer’s Disease Transgenic Mouse Model. [AlzPED] Corticotropin-Releasing Factor Receptor-1 Antagonism Reduces Oxidative Damage in an Alzheimer’s Disease Transgenic Mouse Model. Clinical Trial Effects of Atomoxetine in Mild Cognitive Impairment Study of Melatonin: Sleep Problems in Alzheimer's Disease Memory Impairment Study (Mild Cognitive Impairment Study) Pagination Page 1 Next page ››
